Treatment of severe refractory immune neutropenia with ruxolitinib: Two cases
We describe two cases of severe refractory immune neutropenia: One with T-large granular lymphocyte leukemia and one with chronic idiopathic neutropenia. The JAK inhibitor ruxoltinib restored normal neutrophil counts and was well tolerated in both cases. Further investigation of ruxolitinib as a treatment for immune neutropenia is warranted.
Authors
- Janet Roberts (ORCID: https://orcid.org/0000-0002-3787-8541)
- Richard Schwarzkopf
- Julia Varghese (ORCID: https://orcid.org/0000-0002-4424-634X)
- A Chen
- Stephanie Quon (ORCID: https://orcid.org/0000-0001-9188-8380)
- Luke Y. C. Chen (ORCID: https://orcid.org/0000-0002-9551-2951)
- Richard K. Wood (ORCID: https://orcid.org/0000-0002-2523-890X)
Institutions
- Dalhousie University (CA)
- University of British Columbia (CA)
Publication Details
- Journal
- Journal of Human Immunity
- Published
- 2025-08-27
- DOI
- https://doi.org/10.70962/jhi.20250131
- Primary Topic
- Blood disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Recordati Rare Diseases